UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
4mNpr6
4mNpr6
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Presentations<br />
Sensitizing the hypoxic tumor microenvironment with OMX,<br />
a breakthrough oxygen delivery protein: From protein engineering<br />
to clinical trial<br />
Authors*: Ana Krtolica, Natacha Le Moan, Philberta Leung, Youngho Seo, Jonathan Winger,<br />
Henry Van Brocklin, Michael Kent, Stephen Cary<br />
Pres #: 2790 Section: 5 Presentation Date/Time: Tuesday, April 19: 8:00AM-12:00PM<br />
Location:<br />
Presentation Type: Poster Session<br />
Van Brocklin Lab Expertise: The VanBrocklin laboratory focuses on developing nuclear imaging agents<br />
targeting cell surface proteins (receptors, enzymes and transporters) and signalling pathways and mechanisms<br />
by PET and SPECT imaging. We have developed imaging agents covering a broad range of molecular motifs<br />
from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies), and aptamers, to<br />
proteins and peptides. We synthesize, evaluate and validate tracer mechanisms of localization and retention at<br />
the target site. We utilize in vitro and in vivo model systems to test the probes and interpret the data collected<br />
from these systems to determine their utility for research or as a future diagnostic. We have successfully<br />
translated many of these tracers into humans for drug development or evaluation as future diagnostics.<br />
http://cancer.ucsf.edu/people/profiles/vanbrocklin_henry.3696<br />
__________________________________________________________________________<br />
TPX2 overexpression is essential for the survival of MYC-driven<br />
triple negative breast cancer<br />
Authors*: Julia Rohrberg, Alexandra Corella, Sanjeev Balakrishnan, Andrei Goga<br />
Pres #: 2822 Section: 6 Presentation Date/Time: Tuesday, April 19: 8:00AM-12:00PM<br />
Location:<br />
Presentation Type: Poster Session<br />
Goga Lab Expertise: Tumor cells are driven to proliferate, alter their metabolism, and deregulate cell death<br />
pathways by oncogene over-expression or the loss of tumor-suppressor genes. We seek to understand<br />
how oncogenes alter these pathways using cell-based and transgenic animal models. We are especially<br />
interested in how the prototypical oncogene Myc acts in diverse tumor types, including amongst the most<br />
aggressive breast and liver cancers and lymphomas. Myc has also been postulated to drive a ‘stem cell like’<br />
gene expression pattern which may regulate tumor stem cell function. We seek to elucidate the genes and<br />
pathways that are indispensable for Myc function, and thus uncover potential ‘achilles heels’ of tumor cells.<br />
Our ultimate goal is to translate our basic discoveries to novel cancer therapeutics.<br />
http://oncogenes.net/Goga_Lab/Home.html<br />
*<strong>UCSF</strong> authors in bold<br />
30
Change language